255 related articles for article (PubMed ID: 10753463)
1. N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Rotella DP; Sun Z; Zhu Y; Krupinski J; Pongrac R; Seliger L; Normandin D; Macor JE
J Med Chem; 2000 Apr; 43(7):1257-63. PubMed ID: 10753463
[TBL] [Abstract][Full Text] [Related]
2. Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
Yu G; Mason HJ; Wu X; Wang J; Chong S; Dorough G; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Adam L; Krupinski J; Macor JE
J Med Chem; 2001 Mar; 44(7):1025-7. PubMed ID: 11297448
[No Abstract] [Full Text] [Related]
3. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E
Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
[TBL] [Abstract][Full Text] [Related]
4. Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors.
Rotella DP; Sun Z; Zhu Y; Krupinski J; Pongrac R; Seliger L; Normandin D; Macor JE
J Med Chem; 2000 Dec; 43(26):5037-43. PubMed ID: 11150175
[TBL] [Abstract][Full Text] [Related]
5. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
Wallis RM; Corbin JD; Francis SH; Ellis P
Am J Cardiol; 1999 Mar; 83(5A):3C-12C. PubMed ID: 10078537
[TBL] [Abstract][Full Text] [Related]
6. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors.
Wang Y; Chackalamannil S; Hu Z; Boyle CD; Lankin CM; Xia Y; Xu R; Asberom T; Pissarnitski D; Stamford AW; Greenlee WJ; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2002 Nov; 12(21):3149-52. PubMed ID: 12372521
[TBL] [Abstract][Full Text] [Related]
8. Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
Rosen RC; Kostis JB
Am J Cardiol; 2003 Nov; 92(9A):9M-18M. PubMed ID: 14609619
[TBL] [Abstract][Full Text] [Related]
9. Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule.
Bunnage ME; Mathias JP; Wood A; Miller D; Street SD
Bioorg Med Chem Lett; 2008 Dec; 18(23):6033-6. PubMed ID: 18951784
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases.
Seftel AD
Curr Pharm Des; 2005; 11(31):4047-58. PubMed ID: 16378510
[TBL] [Abstract][Full Text] [Related]
11. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
De Young L; Yu D; Freeman D; Brock GB
Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136
[TBL] [Abstract][Full Text] [Related]
12. The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5.
Wallis RM
Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():22P-26P. PubMed ID: 10629850
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.
Hallén K; Wiklund NP; Gustafsson LE
Br J Pharmacol; 2007 Feb; 150(3):353-60. PubMed ID: 17179943
[TBL] [Abstract][Full Text] [Related]
14. Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
Bioorg Med Chem Lett; 2004 Mar; 14(6):1577-80. PubMed ID: 15006407
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
Yoo J; Thai KM; Kim DK; Lee JY; Park HJ
Bioorg Med Chem Lett; 2007 Aug; 17(15):4271-4. PubMed ID: 17553682
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activities of novel beta-carbolines as PDE5 inhibitors.
Sui Z; Guan J; Macielag MJ; Jiang W; Qiu Y; Kraft P; Bhattacharjee S; John TM; Craig E; Haynes-Johnson D; Clancy J
Bioorg Med Chem Lett; 2003 Feb; 13(4):761-5. PubMed ID: 12639576
[TBL] [Abstract][Full Text] [Related]
17. Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
Yu G; Mason H; Wu X; Wang J; Chong S; Beyer B; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Ferrer P; Zhang R; Adam L; Humphrey WG; Krupinski J; Macor JE
J Med Chem; 2003 Feb; 46(4):457-60. PubMed ID: 12570368
[TBL] [Abstract][Full Text] [Related]
18. Novel PDE5 inhibitors for the treatment of male erectile dysfunction.
Kalsi JS; Bahadur G; Muneer A; Ozturk O; Christopher N; Ralph DJ; Minhas S
Reprod Biomed Online; 2003; 7(4):456-61. PubMed ID: 14656408
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular data on sildenafil citrate: introduction.
Zusman RM
Am J Cardiol; 1999 Mar; 83(5A):1C-2C. PubMed ID: 10078536
[No Abstract] [Full Text] [Related]
20. Phosphodiesterase-5 inhibitors and their hemodynamic effects.
Prisant LM
Curr Hypertens Rep; 2006 Aug; 8(4):345-51. PubMed ID: 16884667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
